Evotec (ETR:EVT) Trading Down 6.7% – Time to Sell?

Evotec SE (ETR:EVT)’s stock price was down 6.7% during mid-day trading on Wednesday . The stock traded as low as €5.23 and last traded at €5.30. Approximately 1,386,983 shares traded hands during mid-day trading, an increase of 2% from the average daily volume of 1,360,000 shares. The stock had previously closed at €5.69.

Evotec Trading Down 3.3%

The firm has a market capitalization of $1.01 billion, a P/E ratio of -5.91, a price-to-earnings-growth ratio of 0.98 and a beta of 1.05. The stock has a 50-day simple moving average of €5.99 and a two-hundred day simple moving average of €5.99. The company has a current ratio of 2.12, a quick ratio of 2.97 and a debt-to-equity ratio of 60.57.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.